These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17440729)

  • 1. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
    Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):395-420. PubMed ID: 15853438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
    Choi HK; Seeger JD; Kuntz KM
    J Rheumatol; 2002 Jun; 29(6):1156-65. PubMed ID: 12064828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.
    Tosh JC; Wailoo AJ; Scott DL; Deighton CM
    J Rheumatol; 2011 Aug; 38(8):1593-600. PubMed ID: 21572149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
    Stephens S; Botteman MF; Cifaldi MA; van Hout BA
    BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.